SHARPIN and melanoma: We again inoculated the opposing flanks of mice with WT or SHARPIN-deficient B16F1 melanomas cells, and 10 days later, when both tumors were detectable and of similar size, we initiated therapy with anti-PD1 mAb or isotype control.